{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:31:53Z","timestamp":1791304313936,"version":"4.3.1"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.imlet.2025.106983","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T16:55:55Z","timestamp":1739206555000},"page":"106983","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Efficacy and safety of efgartigimod in patients with neurological autoimmune diseases"],"prefix":"10.1016","volume":"273","author":[{"given":"Jin","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lipin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiewen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.imlet.2025.106983_bib0001","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s11481-021-10004-9","article-title":"The role of plasma exchange in the treatment of refractory autoimmune neurological diseases: a narrative review","volume":"16","author":"Jacob","year":"2021","journal-title":"J. Neuroimmune Pharmacol."},{"issue":"3","key":"10.1016\/j.imlet.2025.106983_bib0002","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s13311-022-01223-w","article-title":"Anti-complement agents for autoimmune neurological disease","volume":"19","author":"McCombe","year":"2022","journal-title":"Neurotherapeutics."},{"issue":"3","key":"10.1016\/j.imlet.2025.106983_bib0003","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.amjmed.2017.10.033","article-title":"Autoimmune neurologic disorders","volume":"131","author":"Rubin","year":"2018","journal-title":"Am. J. Med."},{"issue":"3","key":"10.1016\/j.imlet.2025.106983_bib0004","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s13311-022-01196-w","article-title":"Evolution of anti-B cell therapeutics in autoimmune neurological diseases","volume":"19","author":"Stathopoulos","year":"2022","journal-title":"Neurotherapeutics."},{"key":"10.1016\/j.imlet.2025.106983_bib0005","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8857486","article-title":"The role of nanomaterials in stroke treatment: targeting oxidative stress","volume":"2021","author":"Song","year":"2021","journal-title":"Oxid. Med. Cell Longev."},{"issue":"3","key":"10.1016\/j.imlet.2025.106983_bib0006","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1074\/mcp.M116.064675","article-title":"A two-pronged binding mechanism of IgG to the neonatal fc receptor controls complex stability and IgG serum half-life","volume":"16","author":"Jensen","year":"2017","journal-title":"Mol. Cell Proteomics."},{"issue":"3","key":"10.1016\/j.imlet.2025.106983_bib0007","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaci.2020.07.015","article-title":"Neonatal Fc receptor in human immunity: function and role in therapeutic intervention","volume":"146","author":"Patel","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"10","key":"10.1016\/j.imlet.2025.106983_bib0008","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.tips.2018.07.007","article-title":"Targeting FcRn to generate antibody-based therapeutics","volume":"39","author":"Ward","year":"2018","journal-title":"Trends. Pharmacol. Sci."},{"issue":"8","key":"10.1016\/j.imlet.2025.106983_bib0009","first-page":"1637","article-title":"FcRn inhibitors: a novel option for the treatment of myasthenia gravis","volume":"18","author":"Zhu","year":"2023","journal-title":"Neural Regen. Res."},{"issue":"10","key":"10.1016\/j.imlet.2025.106983_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102366","article-title":"Next-generation Fc receptor-targeting biologics for autoimmune diseases","volume":"18","author":"Zuercher","year":"2019","journal-title":"Autoimmun. Rev."},{"issue":"10","key":"10.1016\/j.imlet.2025.106983_bib0011","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"23","key":"10.1016\/j.imlet.2025.106983_bib0012","doi-asserted-by":"crossref","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology."},{"issue":"7","key":"10.1016\/j.imlet.2025.106983_bib0013","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"issue":"10413","key":"10.1016\/j.imlet.2025.106983_bib0014","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1016\/S0140-6736(23)01460-5","article-title":"Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Broome","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.imlet.2025.106983_bib0015","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ajh.25680","article-title":"Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia","volume":"95","author":"Newland","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.imlet.2025.106983_bib0016","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bjd.20782","article-title":"Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial","volume":"186","author":"Goebeler","year":"2022","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"10.1016\/j.imlet.2025.106983_bib0017","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","article-title":"Efgartigimod: first approval","volume":"82","author":"Heo","year":"2022","journal-title":"Drugs"}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016524782500015X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016524782500015X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T03:38:50Z","timestamp":1741491530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016524782500015X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":17,"alternative-id":["S016524782500015X"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2025.106983","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of efgartigimod in patients with neurological autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2025.106983","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V. on behalf of European Federation of Immunological Societies.","name":"copyright","label":"Copyright"}],"article-number":"106983"}}